ESTRELLA IMMUNOPHARMA, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $145.30 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-13
- ESTRELLA IMMUNOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $145.30K, a 8.67% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $146.71K, a 7.78% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $152.42K.
- ESTRELLA IMMUNOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $159.10K.
- ESTRELLA IMMUNOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $618.97K.
- ESTRELLA IMMUNOPHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $1.19M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $145.30K 10-Q · filed 2026-08-13 | $292.01K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $146.71K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $618.97K 10-K · filed 2026-03-18 | |||
| 2025-09-30 | $152.42K 10-Q · filed 2025-11-12 | $311.52K derived: sum of 2 quarters · filed 2026-08-13 | $470.61K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $159.10K 10-Q · filed 2026-08-13 | $318.19K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $159.09K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $432.26K 10-K · filed 2026-03-18 | |||
| 2024-06-30 | $1.19M 10-KT · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |